AstraZeneca plans to list its shares in New York while keeping its London listing, a move that could allow easier access to ...
It’s the question biotech investors were wagging about all Monday after Tidmarsh used his personal LinkedIn page to raise ...
GSK announced that Luke Miels, the company’s chief commercial officer, will take over as CEO on Jan. 1, replacing Emma ...
A federal judge in Texas threw out a Biden-era rule last week that would have ramped up federal audits of private Medicare ...
Study finds 99% of all heart attacks, heart failure, or strokes occur in people with "suboptimal" blood pressure, cholesterol ...
Lisa Suennen: "If this is going to make it a lot more expensive to get the same outcome, that is not a good investment." ...
In today's Morning Rounds newsletter, burning questions on MMR vaccines, a perimenopause business boom, and more.
Insurance companies continue to innovate. On Oct. 1, Cigna will roll out a policy that tracks how physicians bill. It will ...
Francer is Lilly’s vice president, head of global regulatory policy and strategy. Cruz is Lilly’s senior vice president, ...
The more we talk, debate, even sometimes argue, the more we can live well with a mind altered by these progressive, disabling ...
Perimenopause brings real symptoms and a booming market of supplements, apps, and therapies. What’s hype, what’s helpful, and ...
GSK CEO Emma Walmsley is stepping down next year after leading the company since 2017, aiming to pivot the U.K. firm into an innovative pharma company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback